Posted by Michael Wonder on 03 Oct 2018
Pfizer launches biosimilar filgrastim, Nivestym, at a substantial discount
3 October 2018 - Pfizer indicated that Nivestym will be priced at a wholesale acquisition cost of $350.40 per 480 mcg pre-filled syringe, a cost that is 30.3% lower than that of the reference Neupogen.
A representative from Pfizer told The Center for Biosimilars in an email that Nivestym, an FDA-approved biosimilar filgrastim (referencing Neupogen), became commercially available in the United States on October 1. Pfizer began shipping the biosimilar to wholesalers on September 24.
Pfizer indicated that Nivestym will be priced at a wholesale acquisition cost of $350.40 per 480 mcg pre-filled syringe, a WAC that is 30.3% lower than that of the reference Neupogen, 20.3% lower than that of Zarxio (Sandoz’s biosimilar filgrastim), and 14.1% lower than that of Granix (or tbo-filgrastim, Teva’s follow-on filgrastim product cleared by the FDA prior to the establishment of a biosimilar approval pathway).
